Preferred Label : ALK Inhibitor PLB 1003;
NCIt definition : An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic
lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration,
PLB1003 selectively binds to and inhibits wild-type ALK, ALK fusion proteins and ALK
point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated
signaling and inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs
to the insulin receptor superfamily and plays an important role in nervous system
development. ALK is not expressed in healthy adult human tissue but ALK dysregulation
and gene rearrangements are associated with a series of tumors. ALK mutations are
associated with acquired resistance to small molecule tyrosine kinase inhibitors.;
Molecule name : PLB-1003; PLB 1003;
NCI Metathesaurus CUI : CL551132;
Origin ID : C148533;
UMLS CUI : C4725107;
Semantic type(s)
- concept_is_in_subset
- has_target
